Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00480974
Status:
COMPLETED
Last Update Posted:
2009-09-04
First Post:
2007-05-31
Brief Title:
Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea
Sponsor:
HaEmek Medical Center Israel
Organization:
HaEmek Medical Center Israel
Study Overview
Official Title:
Long Term Follow up in Sickle Cell Patients Treated by HydroxyureaObservational Retrospective Study
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA Several studies were published with relative short term follow up in pediatric and young adult age The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood
Detailed Description:
Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA Several studies were published with relative short term follow up in pediatric and young adult age The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood
A long term follow up will be recorded in a cohort of twenty SCA patients treated by Hydroxyurea for a period between 5 to 12 years The frequency of vaso-occlusive crises acute chest syndrome blood transfusions and hospitalization will be recorded retrospectively Also the mean hgb level and hgb F percentage will be summarized
A long term follow up will be recorded in a cohort of twenty SCA patients treated by Hydroxyurea for a period between 5 to 12 years The frequency of vaso-occlusive crises acute chest syndrome blood transfusions and hospitalization will be recorded retrospectively Also the mean hgb level and hgb F percentage will be summarized
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None